Price To Earnings Ratio 68.14 | Sector PE 61.04 |
PB Ratio 16.46 | Sector PB 9.01 |
EPS 48.94 | Dividend Yield 1.08 |
Today's Volume 323.784 K | 5 Day Avg. Volume 350.843 K |
PEG Ratio 2.06 | Market Cap. ₹ 1,20,000.00 Cr. |
Time | TORNTPHARM | VS | Industry |
---|---|---|---|
1 Day | -4.64% | -1.52% | |
1 Week | -1.04% | -0.03% | |
1 Month | -0.72% | -3.23% | |
6 Months | 21.17% | 19.89% | |
1 Year | 87.51% | 58.97% |
Period (Days) | SMA | Indication |
---|---|---|
10 | 3445.01 | Bearish |
20 | 3439.82 | Bearish |
30 | 3439.56 | Bearish |
50 | 3389.43 | Bearish |
100 | 3125.65 | Bullish |
200 | 2840.84 | Bullish |
Annual | FY 2024 | FY 2023 | FY 2022 | ||||
---|---|---|---|---|---|---|---|
Operating Activities | 3266.08 | 2368.13 | 1802.99 | ||||
Investing Activities | -167.90 | -2415.31 | -196.63 | ||||
Financing Activities | -2779.64 | 77.36 | -1781.05 | ||||
Net Cash Flow | 318.54 | 30.18 | -174.69 |
All Figures in ₹ Cr., unless mentioned otherwise
Name | 1D (%) | 1W (%) | 1M (%) | 6M (%) | 1Y (%) |
---|---|---|---|---|---|
Torrent Pharmaceuticals | -4.64 | -1.04 | -0.72 | 21.17 | 87.51 |
Alembic | 0.22 | -3.56 | -12.22 | 2.7 | 2.7 |
Aurobindo Pharma | -5.02 | -0.79 | -4.67 | 18.58 | 62.58 |
Fortis Healthcare | 1.25 | 3.87 | 9.59 | 32.63 | 88.24 |
Ajanta Pharmaceuticals | 0.09 | -1.1 | -2.15 | 45.62 | 87.71 |
Torrent Pharmaceuticals Limited is an Indian pharmaceutical company. The company's field of activity is the research, development, production and marketing of generic medicines. It operates in the therapeutic segments Cardiovascular (CV), Gastrointestinal (GI), Central and Central Nervous System, and Vitamin, Mineral Nutrients (VMN). It is also used in therapeutic areas such as anti-epileptic drugs, diabetes treatment, anti-cancer drugs, anti-acne drugs, corticosteroids and cosmetics. It is complex dosage forms developed for the global market based on oral solids, injections, inhalation technologies, long-term depot injections for ophthalmic, nasal, semi-solids for external use and multiparticulate sustained-release oral systems. The company develops various in-house new chemical entities (NCE) in the areas of metabolic, cardiovascular, gastrointestinal, dermatology and respiratory diseases. It is represented in more than 40 countries.